Related Experiment Video
Updated: Dec 16, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study
Jean W Liew1, John D Reveille2, Maria Castillo3
1J.W. Liew, MD, MS, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, Washington; jwliew@uw.edu.
Insights
Cardiovascular disease risk in axial spondyloarthritis (axSpA) patients is similar to the general population when matched for age, sex, and race. Further research is needed for better CV risk prediction in axSpA.
Area of Science:
- Rheumatology
- Cardiology
- Epidemiology
Background:
- Cardiovascular (CV) morbidity and mortality are elevated in axial spondyloarthritis (axSpA).
- Assessing 10-year atherosclerotic cardiovascular disease (ASCVD) risk is crucial for patient management.
- General population risk scores may not accurately reflect CV risk in axSpA.
Purpose of the Study:
- To compare the 10-year ASCVD risk between axSpA patients and the general US population.
- To evaluate the prevalence of a 10-year ASCVD risk score ≥ 7.5% in axSpA.
- To identify potential disparities in CV risk assessment for axSpA.
Main Methods:
- A cross-sectional study included 211 adults (40-75 years) with ankylosing spondylitis or nonradiographic axSpA.
- Matched general population comparators (NHANES cycles 2009-2014) were used (4:1 ratio).
- Conditional Poisson regression estimated the prevalence ratio for a 10-year ASCVD risk score ≥ 7.5%.
Main Results:
- The mean 10-year ASCVD risk was 6.7% for axSpA and 9.0% for NHANES comparators.
- Prevalence of current smoking and diabetes was higher in NHANES comparators.
- The prevalence ratio for a 10-year ASCVD risk score ≥ 7.5% was 0.96 (95% CI 0.74-1.24).
Conclusions:
- No significant difference in 10-year ASCVD risk score prevalence was found between axSpA patients and matched general population controls.
- General population risk scores may underestimate CV risk in axSpA.
- Improved CV risk prediction models are needed for axSpA patients.
Objective:
Cardiovascular (CV) morbidity and mortality are increased in axial spondyloarthritis (axSpA).We conducted a cross-sectional study evaluating the 10-year atherosclerotic cardiovascular disease (ASCVD) risk in axSpA compared to the general US population.
Methods:
We included 211 adults, 40-75 years old with ankylosing spondylitis (AS) or nonradiographic axSpA from 2 sites, who had available data on comorbidities, medication use, blood pressure measures, and laboratory cholesterol values. General population comparators from the 2009-2014 National Health and Examination Survey (NHANES) cycles were matched 4:1 to subjects, on age, sex, and race. We estimated the prevalence ratio for a 10-year ASCVD risk score ≥ 7.5% comparing axSpA and matched NHANES comparators using conditional Poisson regression.
Results:
Overall, subjects were 53.9 ± 11.2 years old, 69% were male, and 74% were White. The mean 10-year ASCVD risk score was 6.7 ± 6.9% for those with axSpA, and 9.0 ± 10.5% for NHANES comparators. Compared to those with axSpA, the prevalence of current smoking and diabetes was higher among NHANES comparators. The estimated prevalence ratio for a 10-year ASCVD risk score ≥ 7.5% comparing those with axSpA and their age-, sex-, and race-matched comparators was 0.96 (95% CI 0.74-1.24).
Conclusion:
The prevalence of a 10-year ASCVD risk score ≥ 7.5% was not significantly different comparing axSpA patients and those drawn from the general population who were similar in terms of age, sex, and race. Future studies should focus on improved CV risk prediction in axSpA, because underestimation by a general population risk score may potentially explain these results.
More Related Videos
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Assessment of the Cardiovascular System I: Subjective Data
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...

